AMRX PDUFA decision: a negative outcome, -11.7%

On June 15, 2018, Amneal Pharmaceuticals, Inc. reached its PDUFA decision. The result was a negative outcome, and the stock moved -11.7% in the window around the event. It had already run +14.0% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.